

**MELANOMA DISEASE SITE COMMITTEE**

THE CHELSEA HOTEL, TORONTO, ON

ROOM: SCOTT

DATE: SUNDAY MAY 5, 2019

TIME: 8:00 AM – 12:00 PM

CHAIR: DR. TERESA PETRELLA

SENIOR INVESTIGATOR : DR. JANET DANCEY

- 
- |                |  |             |
|----------------|--|-------------|
| 8:00 - 8:15 am | <b>Welcome and Approval of 2018 Spring Meeting Minutes</b>   | T. Petrella |
| 8:15 - 8:45 am | <b>Rapid Trial Updates (awaiting analysis, recently closed, previously approved proposals)</b>   |             |
|                | <ul style="list-style-type: none"> <li>• MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG) <span style="float: right;">T. Petrella</span></li> <li>• MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG) <span style="float: right;">T. Petrella</span></li> <li>• ME14 - Prophylactic mesalamine to reduce immune-related AEs with combination ipilimumab / nivolumab in metastatic melanoma <span style="float: right;">T. Petrella</span></li> <li>• MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance) <span style="float: right;">M.Butler</span></li> <li>• IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases <span style="float: right;">T. Petrella</span></li> <li>• ME.15 - Melanoma Margins Trial (MeIMarT) II: A Phase III multi-centre, randomised controlled trial investigating 1 cm vs 2 cm wide excision margins for AJCC stage II primary cutaneous melanoma <span style="float: right;">F. Wright</span></li> </ul> |             |
| 8:45 - 9:30 am | <b>Trial Updates (ongoing / planned)</b>   |             |
|                | <ul style="list-style-type: none"> <li>• ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP) <span style="float: right;">T. Baetz/<br/>X. Song</span></li> </ul>   |             |

9:30 – 9:45 am **Report from IND** J. Dancey

9:45 - 10:00 am **Break**

10:00 - 12:00 pm **New Proposals / Working Group Updates**

- Surgical Working Group F. Wright
- Neo-Adjuvant Working Group X. Song
- Adjuvant Working Group S. Ernst / R. Jamal
- Metastatic Working Group M. Ong / T. Baetz
- Surveillance Working Group C. Nessim
- IND proposal M. Ong

12:00 pm **Meeting Adjourned**

*12:00 - 1:00 pm Executive Committee meeting to follow (closed)*